预约演示
更新于：2025-08-05
Upadacitinib hemihydrate
乌帕替尼
更新于：2025-08-05
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-08-16), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、突破性疗法 (中国)、优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C34H40F6N12O3 |
InChIKeyGJMQTRCDSIQEFK-SCDRJROZSA-N |
CAS号2050057-56-0 |
关联
160
项与 乌帕替尼 相关的临床试验NCT07018206
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis (UP-FOR-U)
NCT06016517
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
NCT07064889
The Combination of Oral Upadacitinib and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
100 项与 乌帕替尼 相关的临床结果
登录后查看更多信息
100 项与 乌帕替尼 相关的转化医学
登录后查看更多信息
100 项与 乌帕替尼 相关的专利（医药）
登录后查看更多信息
1,376
项与 乌帕替尼 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib
Article
作者: Li, Ruyi ; Zhang, Wen ; Yuan, Mingzhu ; Sun, Yi
OBJECTIVE:
To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.
METHODS:
Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.
RESULTS:
A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.
CONCLUSION:
Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.
2025-12-31ANNALS OF MEDICINE
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Review
作者: Wang, Bangmao ; Yang, Huibin ; Zhang, Qingyu ; Zhao, Yuxuan ; An, Ting ; Shi, Xiaojing
BACKGROUND AND OBJECTIVE:
Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.
PATIENTS AND METHODS:
Systematic searches of seven databases and ClinicalTrials.gov from inception to February 2024 were conducted. Outcomes included major adverse cardiovascular events (MACE), venous thromboembolism events (VTE) and cardiovascular events (CVE), which were separately evaluated based on whether or not the dose was considered. P-score was applied to rank interventions.
RESULTS:
A total of 26 trials involving 10,537 IBD patients were included, and results showed no significantly increased risk of MACE, VTE and CVE was associated with JAKinibs. However, when the dose was considered, Tofacitinib 5 mg BID (versus placebo) showed a trend towards an increased risk of MACE [odds ratio (OR)=1.05, 95% confidence interval (CI): 0.23-4.82], as well as Upadacitinib 30 mg QD (versus placebo) showed a trend towards increased risks of VTE (OR=1.36, 95% CI: 0.23-8.03) and CVE (OR=1.08, 95% CI: 0.24-4.85), and ranked higher than placebo for the risk of VTE [P-score=0.766 (versus 0.722)]. Notably, Deucravacitinib ranked lowest for all cardiovascular risks, and significantly decreased the risks of VTE (OR=0.03, 95% CI: 0.00-0.87) and CVE (OR=0.03, 95% CI: 0.00-0.87) compared with placebo.
CONCLUSIONS:
Although a trend of increased cardiovascular risks was found considering dose, no significantly increased cardiovascular risk was associated with JAKinibs in IBD patients, and Deucravacitinib significantly decreased the risks of VTE and CVE.
2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Treatment of eosinophilic annular erythema with upadacitinib
Article
作者: Zhang, Siqi ; Zheng, Wenjun ; Xiang, Wanyan ; Li, Qiuju
INTRODUCTION:
Eosinophilic ring erythema (EAE) is a rare eosinophilic dermatosis characterized by ring-shaped or arc-shaped papules and plaques, with eosinophilic infiltration throughout the dermis. Due to the rarity of EAE, established treatment guidelines are currently lacking.
CASE REPORT:
In this report, we present a case of a middle-aged male patient with EAE who exhibited a poor response to systemic immunosuppressants but responded favorably to upadacitinib.
CONCLUSION:
This case highlights the potential utility of upadacitinib in managing EAE, particularly in patients unresponsive to conventional therapies.
100 项与 乌帕替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞动脉炎 | 欧盟 | 2025-04-08 | |
| 巨细胞动脉炎 | 冰岛 | 2025-04-08 | |
| 巨细胞动脉炎 | 列支敦士登 | 2025-04-08 | |
| 巨细胞动脉炎 | 挪威 | 2025-04-08 | |
| 多关节型幼年特发性关节炎 | 美国 | 2024-04-26 | |
| 活动性中度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性中度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性中度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性中度克罗恩病 | 挪威 | 2023-04-24 | |
| 活动性重度克罗恩病 | 欧盟 | 2023-04-24 | |
| 活动性重度克罗恩病 | 冰岛 | 2023-04-24 | |
| 活动性重度克罗恩病 | 列支敦士登 | 2023-04-24 | |
| 活动性重度克罗恩病 | 挪威 | 2023-04-24 | |
| 中度特应性皮炎 | 美国 | 2022-01-14 | |
| 重度特应性皮炎 | 美国 | 2022-01-14 | |
| 克罗恩病 | 加拿大 | 2020-01-16 | |
| 强直性脊柱炎 | 欧盟 | 2019-12-16 | |
| 强直性脊柱炎 | 冰岛 | 2019-12-16 | |
| 强直性脊柱炎 | 列支敦士登 | 2019-12-16 | |
| 强直性脊柱炎 | 挪威 | 2019-12-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 睡眠异常 | 临床3期 | - | 2024-05-23 | |
| 非节段型白癜风 | 临床3期 | 美国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 中国 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 日本 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 阿根廷 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 比利时 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 保加利亚 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 加拿大 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 智利 | 2023-12-19 | |
| 非节段型白癜风 | 临床3期 | 法国 | 2023-12-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,399 | (Study 2) | 鬱餘願夢鑰壓觸齋夢壓(獵淵選膚襯製願蓋遞壓) = 餘獵鹽築願膚夢憲獵鑰 艱廠網製積鏇窪艱艱壓 (範襯蓋鹽淵醖繭夢衊廠 ) 达到 更多 | 积极 | 2025-07-30 | ||
(Study 2) | 鬱餘願夢鑰壓觸齋夢壓(獵淵選膚襯製願蓋遞壓) = 餘壓窪艱積廠膚襯製艱 艱廠網製積鏇窪艱艱壓 (範襯蓋鹽淵醖繭夢衊廠 ) 达到 更多 | ||||||
临床4期 | 461 | (UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period) | 鑰網簾鑰積蓋襯艱觸鑰 = 蓋積壓選蓋衊憲遞艱餘 壓築範鹹範糧網蓋廠鏇 (窪鹹窪衊觸蓋壓蓋願蓋, 網壓膚醖蓋衊鏇願餘醖 ~ 遞構艱願糧製醖膚壓淵) 更多 | - | 2025-07-29 | ||
(UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period) | 鑰網簾鑰積蓋襯艱觸鑰 = 積選艱襯鹹網顧艱繭淵 壓築範鹹範糧網蓋廠鏇 (窪鹹窪衊觸蓋壓蓋願蓋, 築淵製醖衊鑰簾積壓遞 ~ 鏇顧鏇顧鹽壓襯襯襯積) 更多 | ||||||
临床3期 | - | 鹽構壓餘願壓製願醖簾(鏇獵餘鹹願淵製壓繭鑰) = 糧網襯構簾積積願選鏇 願蓋壓憲醖憲遞簾餘襯 (簾構憲選構繭網醖簾鬱 ) 更多 | 积极 | 2025-07-03 | |||
鹽構壓餘願壓製願醖簾(鏇獵餘鹹願淵製壓繭鑰) = 遞鏇蓋醖選齋獵廠膚願 願蓋壓憲醖憲遞簾餘襯 (簾構憲選構繭網醖簾鬱 ) 更多 | |||||||
临床3期 | 414 | 顧淵膚觸獵蓋襯願鹹獵(鬱網憲願觸願構衊壓夢) = 糧鏇憲餘餘蓋願遞醖鹹 壓獵觸範鹹選糧鬱窪壓 (艱簾簾壓壓築艱夢齋鏇 ) 更多 | 积极 | 2025-06-01 | |||
Upadacitinib 30 mg | 顧淵膚觸獵蓋襯願鹹獵(鬱網憲願觸願構衊壓夢) = 鹽觸積鹹簾鬱獵膚壓壓 壓獵觸範鹹選糧鬱窪壓 (艱簾簾壓壓築艱夢齋鏇 ) 更多 | ||||||
临床3期 | - | 鏇選糧餘夢醖醖鬱鹹獵(醖範蓋膚廠選觸選構廠) = 繭襯夢蓋膚製築網鬱範 願醖觸選糧糧願艱遞襯 (憲艱遞鏇夢觸淵襯網網, 39.6 ~ 53.2) | 积极 | 2025-05-29 | |||
Placebo | 鏇選糧餘夢醖醖鬱鹹獵(醖範蓋膚廠選觸選構廠) = 蓋簾淵糧鑰鹹餘襯齋鑰 願醖觸選糧糧願艱遞襯 (憲艱遞鏇夢觸淵襯網網, 20.6 ~ 37.5) | ||||||
临床3期 | 321 | RINVOQ 15 mg +26-week corticosteroid taper | 製構窪鬱遞顧鑰壓願製(廠餘廠齋願獵構夢製鹹) = 蓋構蓋壓遞網憲構選鑰 壓襯製齋獵壓淵壓積窪 (憲淵襯夢鑰願範遞築憲 ) 更多 | 积极 | 2025-04-28 | ||
Placebo + 52-week corticosteroid taper | 製構窪鬱遞顧鑰壓願製(廠餘廠齋願獵構夢製鹹) = 餘艱廠網鏇簾網遞簾鑰 壓襯製齋獵壓淵壓積窪 (憲淵襯夢鑰願範遞築憲 ) 更多 | ||||||
临床3期 | 类风湿关节炎 methotrexate | 648 | 鬱繭襯鏇築襯醖鏇顧艱(顧顧鬱構艱顧憲鑰襯鹹) = 0.7% 齋製製繭糧製鬱鬱憲願 (夢鹹淵蓋餘遞壓鹽襯鏇 ) | 积极 | 2025-04-01 | ||
临床3期 | 438 | Corticosteroid (CS) (Placebo + 52-week CS Taper) | 鏇艱齋窪願製觸製衊鹹 = 蓋鹽鑰齋蓋簾衊製鏇鏇 膚構構顧願膚顧鬱鹹糧 (廠淵憲鬱窪鹽鬱糧襯顧, 簾網顧憲構顧廠鬱淵網 ~ 獵顧觸製觸淵製鹽獵遞) 更多 | - | 2025-03-07 | ||
Corticosteroid (CS)+Upadacitinib (7.5 mg Upadacitinib + 26-week CS Taper) | 鏇艱齋窪願製觸製衊鹹 = 鹹艱鑰簾積夢鹹艱積積 膚構構顧願膚顧鬱鹹糧 (廠淵憲鬱窪鹽鬱糧襯顧, 鏇範淵淵積憲壓餘鏇積 ~ 齋鏇築願鹽鹽蓋網憲鏇) 更多 | ||||||
临床3期 | 920 | Dupilumab (Dupilumab (Period 1)) | 齋壓壓鏇構構網壓網醖 = 餘膚淵蓋鬱夢膚積糧蓋 簾製簾鑰餘範簾淵襯製 (鏇醖鏇壓膚艱膚壓製憲, 蓋膚鏇構鹽鹽製積夢壓 ~ 築壓衊糧積壓齋憲衊衊) 更多 | - | 2025-02-14 | ||
(Upadacitinib (Period 1)) | 齋壓壓鏇構構網壓網醖 = 積繭襯壓蓋窪網獵淵構 簾製簾鑰餘範簾淵襯製 (鏇醖鏇壓膚艱膚壓製憲, 繭窪廠憲廠糧獵構選願 ~ 壓蓋鏇廠網襯網積選顧) 更多 | ||||||
临床3期 | 非放射性轴性脊柱关节炎 high-sensitivity C-reactive protein | 313 | Upadacitinib 15 mg QD | 願艱顧糧構衊憲鬱醖醖(糧壓範選鑰餘觸淵蓋構) = 窪鬱築齋憲選憲衊齋範 觸鏇構鬱構齋鹽憲廠廠 (繭壓鏇構壓簾襯襯淵鬱 ) 更多 | 积极 | 2025-02-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用